Orchestra BioMed Holdings, Inc. (OBIO)
NASDAQ: OBIO · Real-Time Price · USD
3.990
+0.120 (3.10%)
Jun 18, 2026, 4:00 PM EDT - Market closed
Orchestra BioMed Holdings Revenue
Orchestra BioMed Holdings had revenue of $110.00K in the quarter ending March 31, 2026, a decrease of -87.33%. This brings the company's revenue in the last twelve months to $32.72M, up 1,033.89% year-over-year. In the year 2025, Orchestra BioMed Holdings had annual revenue of $33.48M with 1,169.22% growth.
Revenue (ttm)
$32.72M
Revenue Growth
+1,033.89%
P/S Ratio
7.30
Revenue / Employee
$380,512
Employees
86
Market Cap
238.92M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 33.48M | 30.84M | 1,169.22% |
| Dec 31, 2024 | 2.64M | -122.00K | -4.42% |
| Dec 31, 2023 | 2.76M | -773.00K | -21.88% |
| Dec 31, 2022 | 3.53M | 4.32M | - |
| Dec 31, 2021 | -782.00K | -6.49M | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fulcrum Therapeutics | 80.00M |
| Codexis | 78.09M |
| Coherus Oncology | 46.88M |
| Foghorn Therapeutics | 28.22M |
| Sol-Gel Technologies | 18.47M |
| Whitehawk Therapeutics | 7.15M |
| Fate Therapeutics | 6.32M |
| AC Immune | 4.62M |
OBIO News
- 1 day ago - Orchestra BioMed Holdings Transcript: Sidoti Small-Cap Virtual Investor Conference - Transcripts
- 4 days ago - Orchestra BioMed Holdings Proxy statement: Proxy filing - Filings
- 16 days ago - Orchestra BioMed Holdings Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 16 days ago - Orchestra BioMed Holdings Slides: Corporate presentation - Filings
- 17 days ago - Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Orchestra BioMed price target lowered to $10 from $12 at B. Riley - TheFly
- 4 weeks ago - Orchestra BioMed to Participate in the Jefferies Global Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Orchestra BioMed price target raised to $13 from $12 at Barclays - TheFly